Latest news

• Sanofi's Dupixent gains asthma approval in Europe

  The companies have big plans for the drug, researching its clinical benefit in other diseases driven by allergic and other type 2 inflammation, including chronic rhinosinusitis with nasal polyps. ... A phase 3 showed that Dupixent significantly improved

• Dupixent helps put Sanofi back on growth track

  Meanwhile, Sanofi and development partner Regeneron have also just reported new data in patients with rhinosinusitis and nasal polyps which could expand its use further.

• Regeneron’s Dupixent and Praluent falls short

  such as asthma, nasal polyps and chronic obstructive pulmonary disease (COPD) “means there is a remarkably broad and deep pipeline within Dupixent itself”.

• GSK starts trial of Nucala to seek alternate indications

  It is estimated that 20-40% of people with nasal polyps also have asthma. ... In general, nasal polyps may be considered a benign disease but in severe cases it can have a significant impact on a patient’s day-to-day living.".

• Sanofi eyes March approval for dupilumab in atopic dermatitis

  Sanofi and Regeneron are also developing dupilumab for other allergic diseases such as asthma, nasal polyps and eosinophilic esophagitis.